Company-reported prevalence
Lonvoguran ziclumeran
Overview
| Field | Value |
|---|---|
| Drug | Lonvoguran ziclumeran (lonvo-z, NTLA-2002) |
| Indication | Hereditary angioedema |
| Disease | Hereditary angioedema (HAE); one figure counts treated patients with type 1 and type 2 HAE |
| Company | Intellia Therapeutics, Inc.; the company describes the product as wholly owned |
| Documents searched | Intellia website home, pipeline, disease focus, clinical trials, and HAE patient story pages (read October 2026; pipeline page last updated April 27, 2026); press releases of September 1, 2022 (orphan drug designation, outside the three-year window), and of 2024 to 2026 naming lonvo-z (RMAT designation, phase 2 results, first patient dosed in phase 3, phase 3 results, additional phase 3 results, initiation of the rolling BLA, second-quarter 2026 results, September 8, 2026 BLA acceptance); Form 10-K for 2025 (filed February 2026); Form 10-Q for the second quarter of 2026; corporate presentation filed with Form 8-K, January 9, 2026; corporate presentation, August 2026 |
| Data as of | October 14, 2026 |
| Prepared by | AI research agent (Claude); not yet reviewed by a person |
Company statements of prevalence
United States
Number treated: Intellia Form 10-K for 2025, February 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number treated: Intellia website, October 2026
“Approximately 7,000 treated HAE patients in the U.S.” (opens the source at this quote in a new tab)
Cited source: 2.1 Castaldo 2025
(opens the full-size image in a new tab)Number treated (type 1 or type 2 HAE): Intellia corporate presentation, August 2026
Cited source: 2.1 Castaldo 2025
(opens the full-size image in a new tab)Europe
No evidence found.
Global
Prevalence: Intellia Form 10-K for 2025, February 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number affected: Intellia corporate presentation, January 2026
Cited source: 2.2 Zuraw 2008
(opens the full-size image in a new tab)Other countries and regions
No evidence found.
Geography not stated
Prevalence: Intellia press release, September 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Sources the company cites
Castaldo 2025
Reference as the company lists it, corporate presentation, August 2026
Reference as the company lists it, website, pipeline page
(opens the full-size image in a new tab)Passage carrying the nearest figure
Zuraw 2008
Reference as the company lists it
Passage carrying the figure
Not quoted: Closed access; the article is a clinical practice review with no abstract on its PubMed record.
References
- Castaldo 2025 (opens in a new tab)
- Intellia Therapeutics (2026) corporate presentation filed with Form 8-K, January 9, 2026 (opens in a new tab)
- Intellia Therapeutics (2026) corporate presentation, August 2026 (opens in a new tab)
- Intellia Therapeutics (2026) Form 10-K for 2025 (opens in a new tab)
- Intellia Therapeutics (2026) press release, September 8, 2026 (opens in a new tab)
- Intellia Therapeutics (2026) website, pipeline page (opens in a new tab)
- Zuraw 2008 (opens in a new tab)